SEC Info℠ | Home | Search | My Interests | Help | Sign In | Please Sign In | ||||||||||||||||||||
®
by the SEC on 7/8/20.As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 6/29/20 Bionik Laboratories Corp. 10-K® 3/31/20 80:6.6M Toppan Merrill/FA |
Document/Exhibit Description Pages Size 1: 10-K Annual Report HTML 690K 2: EX-4.6 Instrument Defining the Rights of Security Holders HTML 27K 4: EX-10.18 Material Contract HTML 26K 3: EX-10.8 Material Contract HTML 24K 5: EX-31.1 Certification -- §302 - SOA'02 HTML 30K 6: EX-31.2 Certification -- §302 - SOA'02 HTML 30K 7: EX-32.1 Certification -- §906 - SOA'02 HTML 23K 8: EX-32.2 Certification -- §906 - SOA'02 HTML 23K 15: R1 Document And Entity Information HTML 58K 16: R2 Consolidated Balance Sheets HTML 93K 17: R3 Consolidated Balance Sheets (Parenthetical) HTML 46K 18: R4 Consolidated Statements of Operations and HTML 79K Comprehensive Loss 19: R5 Consolidated Statements of Changes in HTML 68K Shareholders' Equity 20: R6 Consolidated Statements of Cash Flows HTML 111K 21: R7 Nature of Operations and Going Concern HTML 37K 22: R8 Basis of Presentation HTML 28K 23: R9 Significant Accounting Policies HTML 73K 24: R10 Technology and Other Assets HTML 80K 25: R11 Prepaid Expenses and Other Receivables HTML 40K 26: R12 Inventories HTML 34K 27: R13 Equipment HTML 78K 28: R14 Notes Payable HTML 45K 29: R15 Related Party Transactions and Balances HTML 28K 30: R16 Share Capital HTML 83K 31: R17 Stock Options HTML 223K 32: R18 Warrants HTML 70K 33: R19 Income Taxes HTML 84K 34: R20 Risk Management HTML 26K 35: R21 Commitments and Contingencies HTML 34K 36: R22 Subsequent Events HTML 27K 37: R23 Significant Accounting Policies (Policies) HTML 128K 38: R24 Significant Accounting Policies (Tables) HTML 32K 39: R25 Technology and Other Assets (Tables) HTML 79K 40: R26 Prepaid Expenses and Other Receivables (Tables) HTML 40K 41: R27 Inventories (Tables) HTML 34K 42: R28 Equipment (Tables) HTML 78K 43: R29 Notes Payable (Tables) HTML 33K 44: R30 Share Capital (Tables) HTML 79K 45: R31 Stock Options (Tables) HTML 218K 46: R32 Warrants (Tables) HTML 67K 47: R33 Income Taxes (Tables) HTML 89K 48: R34 Nature of Operations and Going Concern (Details) HTML 51K 49: R35 Basis of Presentation (Details) HTML 27K 50: R36 Significant Accounting Policies (Details) HTML 87K 51: R37 TECHNOLOGY AND OTHER ASSETS - Intangible assets HTML 51K acquired (Details) 52: R38 TECHNOLOGY AND OTHER ASSETS - Additional HTML 27K Information (Details) 53: R39 Prepaid Expenses and Other Receivables (Details) HTML 35K 54: R40 INVENTORIES- Schedule of Inventories (Details) HTML 24K 55: R41 INVENTORIES - Additional Information (Details) HTML 24K 56: R42 EQUIPMENT - Schedule of net equipment (Details) HTML 48K 57: R43 EQUIPMENT - Additional Information (Details) HTML 24K 58: R44 NOTES PAYABLE - Conversion of Notes Payable HTML 42K (Details) 59: R45 Notes Payable (Details) HTML 62K 60: R46 Notes Payable - Short term loan (Details) HTML 34K 61: R47 Related Party Transactions and Balances (Details) HTML 41K 62: R48 SHARE CAPITAL - Common shares issued (Details) HTML 55K 63: R49 SHARE CAPITAL - Additional Information (Details) HTML 85K 64: R50 STOCK OPTION - Black-Scholes Option Pricing Model HTML 96K (Details) 65: R51 STOCK OPTION - Option Activity (Details) HTML 37K 66: R52 STOCK OPTIONS - Summary of stock options HTML 106K outstanding and exercisable (Details) 67: R53 STOCK OPTIONS - Additional Information (Details) HTML 139K 68: R54 WARRANTS - Summary of continuity schedule HTML 44K (Details) 69: R55 WARRANTS - Summary of common share purchase HTML 38K warrants outstanding (Details) 70: R56 WARRANTS - Additional Information (Details) HTML 61K 71: R57 INCOME TAXES - Schedule of reconciliation of the HTML 53K us income tax rate (Details) 72: R58 INCOME TAXES - Schedule of deferred tax assets and HTML 44K liabilities (Details) 73: R59 INCOME TAXES - Income Tax Examination Open Tax HTML 31K Years (Details) 74: R60 INCOME TAXES - Narrative (Details) HTML 28K 75: R61 Risk Management (Details) HTML 38K 76: R62 Commitments and Contingencies (Details) HTML 49K 77: R63 Subsequent Events (Details) HTML 37K 79: XML IDEA XML File -- Filing Summary XML 137K 78: EXCEL IDEA Workbook of Financial Reports XLSX 101K 9: EX-101.INS XBRL Instance -- bnkl-20200331 XML 2.12M 11: EX-101.CAL XBRL Calculations -- bnkl-20200331_cal XML 139K 12: EX-101.DEF XBRL Definitions -- bnkl-20200331_def XML 547K 13: EX-101.LAB XBRL Labels -- bnkl-20200331_lab XML 1.09M 14: EX-101.PRE XBRL Presentations -- bnkl-20200331_pre XML 900K 10: EX-101.SCH XBRL Schema -- bnkl-20200331 XSD 196K 80: ZIP XBRL Zipped Folder -- 0001104659-20-078067-xbrl Zip 158K
Exhibit 32.1
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report of Bionik Laboratories Corp. (the "Company") on Form 10-K for fiscal year ended March 31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Eric Dusseux, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
(1) | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
(2) | The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company. |
Date: June 29, 2020 | |
/s/ Eric Dusseux | |
Eric Dusseux | |
Chief Executive Officer | |
(Principal Executive Officer) |
C:
This ‘10-K’ Filing | Date | Other Filings | ||
---|---|---|---|---|
Changed on / Corrected on: | 7/8/20 | 8-K | ||
Filed on: | 6/29/20 | |||
For Period end: | 3/31/20 | |||
List all Filings |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 6/21/23 Bionik Laboratories Corp. 10-K 3/31/23 78:8.6M Toppan Merrill/FA2 2/08/23 Bionik Laboratories Corp. 10-Q 12/31/22 59:4.8M Toppan Merrill/FA2 11/09/22 Bionik Laboratories Corp. 10-Q 9/30/22 56:4.4M Toppan Merrill/FA2 8/10/22 Bionik Laboratories Corp. 10-Q 6/30/22 48:3.5M Toppan Merrill/FA2 6/09/22 Bionik Laboratories Corp. 10-K 3/31/22 68:7.9M Toppan Merrill/FA2 6/24/21 Bionik Laboratories Corp. 10-K 3/31/21 71:6.3M Toppan Merrill/FA |